

Rheumatology Treatment

Reference Number: F4638
Date of Response: 15th June 2022

Further to your Freedom of Information Act request, please find the Trust's response, in **blue bold text** below:

Royal Devon's Eastern FOI Office Response

Q1. Could you please provide the numbers of patients treated by the **rheumatology** department (for any condition) in the last 3 months with the following drugs:

- Abatacept [Orencia] – **19 patients**
- Adalimumab [Humira] – **20 patients**
- Adalimumab Biosimilars -- **174 patients**
- Apremilast [Otezla] – **8 patients**
- Baricitinib [Olumiant] – **40 patients**
- Certolizumab [Cimzia] – **55 patients**
- Etanercept Biosimilars – **82 patients**
- Filgotinib [Jyseleca] – **28 patients**
- Golimumab [Simponi] – **69 patients**
- Infliximab Biosimilars – **16 patients**
- Ixekizumab [Taltz] – **14 patients**
- Risankizumab [Skyrizi] – **0 patients**
- Rituximab [MabThera] – **0 patients**
- Rituximab Biosimilars – **25 patients**
- Sarilumab [Kevzara] – **5 patients**
- Secukinumab [Cosentyx] – **27 patients**
- Tocilizumab [Ro Actemra] – **31 patients**
- Tofacitinib [Xeljanz] – **25 patients**
- Upadacitinib [Rinvoq] – **37 patients**
- Ustekinumab [Stelara] – **0 patients**

Q2. Could you please provide the numbers of patients treated for Axial Spondyloarthritis ONLY in the last 3 months with the following drugs:

- Adalimumab [Humira] – **10 patients**
- Adalimumab Biosimilars – **40 patients**
- Certolizumab [Cimzia] -- **13 patients**
- Etanercept Biosimilars – **19 patients**
- Golimumab [Simponi] – **25 patients**
- Infliximab [Remicade] – **0 patients**
- Ixekizumab [Taltz] – **0 patients**
- Secukinumab [Cosentyx] – **13 patients**
- Upadacitinib [Rinvoq] -- **0 patients**

In accordance with section 40 (2) of the Freedom of Information Act 2000, We are unable to provide the figures for the following treatments:

- Etanercept [Enbrel]
- Guselkumab [Tremfya]
- Infliximab [Remicade]
- Infliximab Biosimilars (Unable to provide figures for this treatment under question 2)

We can confirm that this data is held by the Trust, however, In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide these figures as the number of patients treated using the above is less than five. Releasing this data could risk the identification of these patients. This would breach Caldicott principles and principle One of the GDPR.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.